Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Homerun Slides: Clinical presentation library Previous | All Articles This Week | Next
This article originally posted and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2

DCMS91HS 

Part 1 of this two-part series covers some of the newest therapies for type 2 diabetes including GLP-1 agonists and DPP-4 inhibitors. We also take a look at some of the even newer therapies on the horizon such as SGLT2 inhibitors, ultra long-acting insulin (degludec) and interleukin-1 blocker, diacerein. 

Link to download (.ppt format): Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 1 of 2.

Other sets in this series:

Diabetes: Exploring the Risks and Benefits of Emerging Type 2 Therapies, Part 2 of 2

Check out all of Diabetes In Control's slide collections at our Clinical Presentations Library.

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 02 July, 2012 and appeared in  Medication SlidesGLP-1Diabetes Clinical Mastery Series Issue 91SGLT2

Past five issues: SGLT-2 Inhibitors Special Edition July 2015 | Diabetes Clinical Mastery Series Issue 251 | Issue 791 | Diabetes Clinical Mastery Series Issue 250 | GLP-1 Special Editions July 2015 |

2015 Most Popular Articles:

Self-Monitoring of Blood Glucose: The Patient's Perspective
Posted July 10, 2015
The Impact of Glucagon-Like Peptide 1 Receptor Agonists on Weight Reduction
Posted July 10, 2015
Diet That Mimics Fasting Appears to Slow Aging
Posted July 03, 2015
Vitamin D3 Supplementation and Weight Loss Prevent Cancer in Older Women
Posted July 10, 2015
Evaluation of Cellphone Application that Records Readings from Glucometer
Posted July 10, 2015
Metformin May Increase Mortality in Advanced CKD among Type 2 Patients
Posted July 10, 2015
GLP-1 Receptor Agonists Reduce Bone Loss During Weight Loss
Posted July 17, 2015
Can the Insulin Patch Become a Reality?
Posted July 03, 2015
New Evidence Suggests Pioglitazone Reduces Dementia Risk 42%
Posted July 03, 2015
Ancestral Diets Can Determine Vulnerability to Type 2 Diabetes
Posted July 17, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you have any patients on a dual therapy of a DPP-4 and a SGLT-2 who have reached their goal A1c?